Dare Bioscience, Inc. Common Stock (DARE) Stock Price

DAREStock

$0.82−62.19%52W

Market Cap$15.90M

P/E—

PEG Ratio—

Div yield—

Beta1.06

DARE Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-62.67%

Price vs S&P 500 (4W)-35.41%

VGM Score50.39

P/CF (Annual)4.70x

Book Value / Share (Quarterly)$0.05

P/TBV (Annual)3.04x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-53.12%

Cash Flow / Share (Quarterly)$-0.70

Price vs S&P 500 (YTD)-70.43%

Gross Margin (TTM)54.33%

Net Profit Margin (TTM)-679.26%

EPS (TTM)$-0.59

10-Day Avg Trading Volume1.98M

EPS Excl Extra (TTM)$-0.59

Revenue Growth (5Y)66.71%

EPS (Annual)$-1.20

ROI (Annual)-137.64%

Gross Margin (Annual)71.29%

Net Profit Margin (5Y Avg)-14661.44%

Cash / Share (Quarterly)$1.27

Revenue Growth QoQ (YoY)499.53%

ROA (Last FY)-41.26%

Revenue Growth TTM (YoY)1215.77%

EBITD / Share (TTM)$-0.47

ROE (5Y Avg)-867.89%

Operating Margin (TTM)-690.96%

Cash Flow / Share (Annual)$-0.71

P/B Ratio27.64x

P/B Ratio (Quarterly)36.08x

Net Income / Employee (Annual)$-638,100

EV / Revenue (TTM)6.74x

Net Interest Coverage (TTM)-92.72x

ROA (TTM)-26.37%

EPS Incl Extra (Annual)$-1.20

Current Ratio (Annual)1.14x

Quick Ratio (Quarterly)0.91x

3-Month Avg Trading Volume0.70M

52-Week Price Return-62.19%

EV / Free Cash Flow (Annual)1.98x

Revenue / Employee (TTM)$56,100

Tangible BV / Share (Quarterly)$-0.02

P/S Ratio (Annual)19.70x

Asset Turnover (Annual)0.03x

52-Week High$3.78

Operating Margin (5Y Avg)-12521.20%

EPS Excl Extra (Annual)$-1.20

CapEx CAGR (5Y)80.70%

Tangible BV CAGR (5Y)6.51%

26-Week Price Return-51.42%

Quick Ratio (Annual)1.08x

13-Week Price Return-66.74%

Total Debt / Equity (Annual)2.42x

Current Ratio (Quarterly)1.03x

Enterprise Value$7.94M

Revenue / Share Growth (5Y)10.80%

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)-38.32%

Revenue / Employee (Annual)$49,100

Pretax Margin (Annual)-1300.66%

Cash / Share (Annual)$1.70

3-Month Return Std Dev109.85%

Net Income / Employee (TTM)$-381,200

ROE (Last FY)-471.37%

Net Interest Coverage (Annual)-229.44x

EPS Basic Excl Extra (Annual)$-1.20

P/FCF (TTM)16.40x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)8.40x

EPS Incl Extra (TTM)$-0.59

Receivables Turnover (Annual)0.00x

ROI (TTM)-89.74%

P/S Ratio (TTM)17.22x

Pretax Margin (5Y Avg)-14661.44%

Revenue / Share (Annual)$0.09

Tangible BV / Share (Annual)$0.13

Price vs S&P 500 (52W)-80.50%

Year-to-Date Return-58.47%

5-Day Price Return4.33%

EPS Normalized (Annual)$-1.20

ROA (5Y Avg)-68.25%

Net Profit Margin (Annual)-1300.66%

Month-to-Date Return-34.30%

Cash Flow / Share (TTM)$-0.48

EBITD / Share (Annual)$-1.07

Operating Margin (Annual)-1315.52%

LT Debt / Equity (Annual)1.90x

ROI (5Y Avg)-801.15%

LT Debt / Equity (Quarterly)7.57x

EPS Basic Excl Extra (TTM)$-0.59

P/B Ratio (Annual)9.70x

Pretax Margin (TTM)-679.26%

Book Value / Share (Annual)$0.20

Price vs S&P 500 (13W)-69.54%

Beta1.06x

P/FCF (Annual)4.21x

Revenue / Share (TTM)$0.08

ROE (TTM)-373.17%

52-Week Low$0.75

vGradeD

gGradeA

mGradeD

vgmGradeC

DARE Earnings Surprise History

Q2 25-0.45est. -0.58

Q3 25-0.28est. -0.40

Q4 25-0.10est. -0.42

Q1 26-0.20est. -0.30

Q2 26-0.20est. -0.30

DARE Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.10

4.11

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
DAREDare Bioscience, Inc. Common Stock	D	A	D	$0.82
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Dare Bioscience, Inc. Common Stock

Dare Bioscience is a biopharmaceutical company developing therapies in women's health, focused on contraception, fertility, and sexual health. The company's first approved product, XACIATO, is a prescription vaginal gel for treating bacterial vaginosis in females ages 12 and older. Its pipeline includes two clinical-stage candidates: Ovaprene and Sildenafil Cream.